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Anti-interleukin-la autoantibodies in hemodialysis patients. IL-i ac-
tivity is increased in hemodialysis patients and interest has recently
been focused on IL-I antagonism in various clinical settings. We
studied the presence of anti-IL-i a autoantibodies in sera from 49
hemodialysis patients, 159 kidney graft recipients and 89 chronic renal
failure patients without renal replacement therapy. Within the three
month study period 32.6% of the hemodialysis patients were found to
present with anti-IL-la autoantibodies, in contrast to 5.6% of kidney
graft recipients, 8.9% of chronic renal failure patients, and only 1.4% of
healthy subjects. The presence of these autoantibodies was neither
associated with primary kidney disease nor with the type of dialysis
membrane we used. In addition, in antibody positive patients a pro-
nounced increase of IL-i a serum levels within a dialysis session from
14.8 4.7 pg/mI to 26.4 11.2 pg/mI (P < 0.0005) was observed,
contrasting to the more even increase from 14.1 3.1 pg/mI to 19.3
12.7 pg/mI (P < 0.05) in the antibody negative group. Neither clinical
symptoms due to adverse effects of IL-I a nor some influence on
erythropoiesis mediated by IL-la could be envisaged. Thus, we be-
lieve, that anti-IL-la autoantibodies, present in high frequency in
hemodialysis patients, have a neutralizing effect on IL-la in these
patients.
Interleukin-i (IL-i) is a pleiotropic cytokine which has two
forms, IL-la and IL-1f3, and is predominantly released by the
monocyte/macrophage system [1]. IL-i activity is increased in
patients undergoing hemodialysis treatment due to either com-
plement activation by cellulosic membranes or backfiltration of
endotoxins, even when synthetic membranes are used [2—8].
Adverse effects of IL-i, known in hemodialysis as the "inter-
leukin hypothesis", include fever and hypotension, and were
recently extended to erythrocyte suppressing activity [9, 10].
Search for physiological feedback mechanisms of IL-i synthe-
sis and activity has evolved in the detection of several IL-i
inhibitor molecules, and autoantibodies directed against IL- 1 a
have been identified with low frequency even in healthy donors
[11—14]. An increased presence of these autoantibodies was
recently described in patients with septicemia and rheumatoid
arthritis, implicating a major pathophysiological importance of
these autoantibodies within the cytokine network in human
diseases [14, 15]. We studied the possible involvement of
autoantibodies directed against IL-Ia in hemodialysis patients,
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kidney transplant recipients and chronic renal failure patients,
since little knowledge covers IL-i a antagonism in such pa-
tients.
Methods
Patients
The presence of anti-IL-la autoantibodies was studied in 364
subjects. A total of 297 hospital outpatients suffering from
kidney disease, either maintained on hemodialysis treatment (N
= 49), or having received a kidney transplant (N = 159), or who
were without renal replacement therapy (N = 89) were in-
cluded. Sixty-seven healthy volunteers were included as con-
trols. In a subgroup of hemodialysis patients (N = 43), serum
levels of endogeneous IL- 1 a were determined before and at the
end of their dialysis sessions.
The primary renal disease of 49 hemodialysis patients (22
females, 27 males; mean age: 61 14 years), studied for a
period of three months, was chronic glomerulonephritis in 16,
diabetic nephropathy in 10, both chronic pyelonephntis and
vascular nephropathy in 6, analgesic nephropathy in 5, poly-
cystic kidney disease in 3, and miscellaneous nephropathies in
3 cases. They were maintained on renal replacement therapy for
21 29 months (range: 1 to 142 months), using cellulosic
membranes (GFS plus 120, Gambro, Hechingen, Germany;
MA-l5H, Salvia, Homburg, Germany) in 31, and synthetic
membranes (Hemoflow F6, F4, F60 or F40, Fresenius, Bad
Homburg, Germany; KF-201-N, Salvia) in 18 cases, at least one
month before and throughout the observation period. They
were in a stable state of health without a recent infection
history, without previous kidney transplantation, and they
received no immunosuppressive therapy. Erythropoietin was
administered intravenously at the end of each dialysis session
and the individual dosage was adjusted to reach a hematocrit
value of about 30 to 35%.
Eighty-nine patients without renal replacement therapy (46
females, 43 males; mean age: 52 17 years) showed various
degrees of renal insufficiency (mean serum creatinine: 2.8
2.2, range: 0.7 to 12.4 mg/dI) due to a wide range of renal limited
or systemic diseases, as there were glomerulonephritis in 32,
chronic pyelonephritis in 8, vascular nephropathy in 7, and
diabetic nephropathy, minimal change nephrotic syndrome and
a single kidney following nephrectomy in 6 cases. ANCA
associated vasculitis, analgesic nephropathy and polycystic
kidney disease could be detected in 5 patients, whereas lupus
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Table 1. 32.6% of hemodialysis patients (N = 16) presenting anti IL-Ia autoantibodies
Patient Age Sex
Time on
dialysis Membrane EPO dosage
IL-la pg/mi Anti-IL-la
antibodiesPre- Post-
no. years fim Diagnosis months c/s U/kg body Wi dialysis dialysis % binding
1 44 m IgAGN 8 c 45 9.3 24.3 3.80
2 57 m DN 27 c 109 20.9 41.9 3.94
3 62 m IN 33 c 39 16.8 18.4 4.01
4 23 f MCNS 8 c 46 6.9 24.0 4,54
5 56 f GN 6 s 16 15.0 13.4 4.83
6 77 f DN 2 s 26 11.3 41.8 4.84
7 67 m GN 13 s 41 13.4 23.2 5.87
8 64 m ON 1 c 92 18.0 30.0 6.35
9 53 f ON 90 s 160 10.3 14.6 6.69
10 71 f PN 13 s 0 14.1 19.3 10.36
11 51 m GN 19 s 98 17.4 47.9 11.82
12 51 m PN 14 c 160 13.6 22.9 12.09
13 56 f PKD 7 s 0 18.4 19.3 14.11
14 71 m GN 4 c 68 11.6 21.0 16.39
15 61 f PN 16 s 37 13.7 16.4 31.36
16 28 m ON 5 c 115 25.6 43.3 47.45
Abbreviations are: GN, glomerulonephritis; DN, diabetic nephropathy; IN, interstitial nephritis; MCNS; minimal change nephrotic syndrome;
PN, pyelonephritis; PKD, polycystic kidney disease; c, cellulosic; s, synthethic.
nephritis was present in 4, both Goodpasture syndrome and
interstitial nephntis in 2 and hemolytic uremic syndrome in 1
case.
One hundred and fifty-nine kidney allograft recipients (60
females, 99 males; mean age: 50 13 years), having received
their first transplant 40 42 months prior to this study (range:
I to 215 months), were treated with standard immunosuppres-
sive regimens including cyciosporin A, prednisolone or azathi-
oprine. Their mean serum creatinine was 1.8 0.9 (range: 0.8
to 6.8 mg/dl).
Assays
Anti-IL-i a autoantibodies were determined using a radioim-
munoassay, and measurement of IL-la serum levels was per-
formed with an enzyme immunoassay. Blood samples were
spun immediately after clotting and serum was stored at —20°C.
The reagents for the anti-IL-la autoantibody assay were
obtained from BUhlmann Laboratories AG, Basel, Switzerland.
Following appropriate dilution of serum samples and addition of
'25J..JL 1 a, autoantibody-bound '25J-IL- 1 a was separated from
free '25J-IL-la by immunoprecipitation with rabbit anti-human
IgO, polyethyleneglycol and centrifugation. Results are ex-
pressed as percent IgG-bound '25J-IL-la of total '25J-IL-la
activity. Since one can speculate about a possible influence of
endogeneous IL-I a on '25J-IL- 1 a binding to anti-IL-I a antibod-
ies in our detection system, some antibody positive sera were
spiced with recombinant human IL-la. In this way measure-
ment of anti-IL-la autoantibodies was diminished only at
recombinant human IL- 1 a concentrations far exceeding the
amount of '25J-IL-la applied in our test system or endogeneous
IL-la, present in patients sera (data not shown).
The enzyme immunoassay for IL- 1 a measurement was ob-
tained from Research and Diagnostic Systems (Minneapolis,
Minnesota, USA). In a 'sandwich' technique a monoclonal
anti-IL- 1 a antibody was coated onto a microtiterplate. After
pipetting samples to the wells, an enzyme-linked polyclonal
anti-IL-la antiserum was added, followed by incubation with
the substrate solution. Results are expressed in pg/mi, with a
minimum detectable level of 7 pg IL-l a/mi. Endogeneous IL- 1 a
activity of healthy volunteers was below the detection limit of
this assay system.
Statistical analysis
Data are given as means SD or as ranges. Statistical
analysis was performed with paired or unpaired Students
t-tests; P < 0.05 was considered to be significant.
Results
Anti-IL-i a autoantibodies
Healthy subjects. In 67 healthy volunteers a very low anti-
IL- 1 a autoantibody activity could be observed. Mean binding
of '25J-IL-la was 1.77 0.67% (range: 0.28 to 4.18%), and the
mean plus 3 SD, that is, 3.79% '25J-IL-Ia binding, was consid-
ered to be negative. In this way, only 1 out of 67 controls (1.4%)
presented with anti-IL- 1 a autoantibodies.
Hemodialysis patients. In contrast to healthy volunteers,
32.6% (N = 16) of our hemodialysis patients (N = 49) were
found to have anti-IL-i a autoantibodies, with an average
IL-la binding of 4.95 8.18% in all 49 patients. The 16 patients
considered to be positive for anti-IL-i a autoantibodies showed
3.80 to 47.45% '25J-IL-la binding activity. In 10 of these
patients anti-IL- 1 a activity was constantly detectable through-
out the observation period of three months, whereas six pa-
tients developed autoantibodies within the course of the study.
The other 33 patients remained negative for the whole study
period.
Considering the 16 positive patients, 50% (N = 8) were
treated with celluiosic membranes, whereas the other 50% (N =
8) were on treatment with synthetic dialyzer membranes. Clin-
ical symptoms due to an increased cytokine activity were
neither observed in any of the autoantibody positive hemodial-
ysis patients, nor in any of the autoantibody negative patients.
Additionally, no clear cut association with primary kidney
disease could be found (Table 1). No differences in erythropoi-
etin requirements could be noticed in either dialysis patient
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Table 2. Renal graft recipients (5.6%, N = 9) presenting with anti-
IL-la autoantibodies
Time
Patient
no.
Age
years
Sex
fim
since
NTX
months Diagnosis
Creatinine
mg/dl
Anti-IL-la
antibodies
% binding
1 49 m 61 sgf 1.9 4.86
2 51 m 2 sgf 3.4 7.01
3 67 m 36 sgf 2.0 7.69
4 34 m 53 GN 1.9 9.14
5 48 m 41 sgf 4.8 9.32
6 58 m 53 ON 2.2 21.24
7 54 m I avr 2.0 24.91
8 38 m 28 GN 2.5 26.14
9 31 m 15 sgf 1.2 42.02
Table 3. Chronic renal failure patients (8.9%, N = 8) presenting with
anti-IL-la autoantibodies
Anti-IL-la
Patient
no.
Age
years
Sex
fim Diagnosis
Creatinine
mg/dl
antibodies
% binding
1 48 m epi-GN 0.8 4.75
2 67 f ANCA 7.6 7.54
3 57 m sk 2.1 8.84
4 37 f IgAGN 1.8 24.8
5 67 f AN 3.6 33.25
6 33 m PKD 1.7 34.91
7 60 f ON 5.3 40.77
8 68 m REF 3.5 58.34
groups. Mean erythropoietin dosage throughout the study pe-
nod of three months was 57 46 U/kg body wt (range: 0 to 160)
in the autoantibody positive group, and 58 39 U/kg body wt
(range: 0 to 181) in the autoantibody negative group, P < 0.5.
Kidney graft recipients. Out of 159 kidney graft recipients
(average anti-IL-l a activity: 2.34 4.59%) only 5.6% (N = 9,
4.86 to 42.02% binding activity) were found to be positive for
anti-IL-la autoantibodies. Four of them presented with acute
deterioration of graft function due to acute vascular rejection in
1 case and due to biopsy proven glomerulonephritis in 3 cases,
whereas 5 patients were in a stable state of health (Table 2).
Neither CMV disease nor bacterial infections were present in
these cases.
Chronic renal failure patients. Similar to transplant patients,
autoantibodies could be detected in 8.9% of 89 chronic renal
failure patients (average anti-IL-la activity: 3.99 8.93%).
These 8 patients presented 4.7 to 58.3% binding. Three of them
(1 case with analgesic nephropathy, 1 with reflux nephropathy
and 1 with chronic glomerulonephritis) suffered from bacterial
urinary tract infection, 4 from acute deterioration of kidney
function (epimembraneous, IgA and ANCA associated glomer-
uionephritis and status postnephrectomy). The remaining pa-
tient suffered from polycystic kidney disease (Table 3).
IL-la
In 43 out of 49 hemoclialysis patients IL- 1 a serum levels were
determined before and at the end of a dialysis session. Low
levels of IL-i a were detectable in all patients. Mean IL-La
activity was 14.4 3.7 pg/mI (range 6.9 to 25.6) with an increase
to 21.9 12.05 pg/mi (range 8.2 to 73.2) at the end of the
dialysis session (P < 0.0005). Comparing IL-la activity of the
anti-IL-la autoantibody positive patients with the anti-IL-la
autoantibody negative group, similar IL-la prevalues (anti-
IL-la autoantibody positive, N = 16: 14.8 4.7 pg/mI, range,
6.9 to 25.6; anti-IL-la autoantibody negative, N = 27: 14.1
3.1 pg/mI, range, 8.3 to 21.8; P < 0.5) could be found. At the
end of the dialysis sessions a pronounced increase of IL-la
serum values could be found in anti-IL-la autoantibody posi-
tive patients, if compared with anti-IL-la autoantibody nega-
tive patients. Mean IL-la serum activity was 26.4 11.2 pg/mI
(range, 13.4 to 47.9, P < 0.0005) in contrast to 19.3 12.7 pg/mI
(range, 8.2 to 73.2, P < 0.05) in the anti-IL-la autoantibody
negative group. Beneath the statistical significant increase of
IL-la in the autoantibody positive group, the post-dialysis
values of both groups were not significantly different per Se.
With respect to the different dialyzer membranes we used, the
increase of IL-l a activity in patients treated with cellulosic
membranes (N = 29) was close to the levels in patients treated
with synthetic membranes (N = 14; 14.33 3.93 to 21.06
13.36 pg/ml, P < 0.05, and 14.34 3.39 to 23.79 10.75 pg/mI,
P < 0.005, respectively).
Discussion
We studied the possible induction of anti-IL-la autoantibod-
ies in hemodialysis patients, kidney graft recipients and patients
with various degrees of renal insufficiency due to a wide range
of systemic or renal limited diseases. Hemodialysis patients
were found to produce anti-IL- 1 a autoantibodies in a very high
percentage (32.6%), if compared with healthy donors (1.4%),
kidney graft recipients (5.6%) or othe'- chronic renal failure
patients (8.9%).
Our finding of the very low prevalence of anti-IL- 1 a auto-
antibodies in normal volunteers is in contrast to the results of
Bendtzen and colleagues, who found a presence of anti-IL-la
autoantibodies in 10 to 24% of healthy volunteers [12, 13].
However, Suzuki and colleagues, who recently reported anti-
IL-la IgG in 17% of sera from rheumatoid arthritis patients,
detected anti-IL- 1 a IgG in only 2% of normal donor sera, which
is in keeping with our findings of 1.4% antibody positivity in
normal subjects [15]. The previously mentioned differences
might be due to the methods used for detecting autoantibodies.
Furthermore, regional and ethnic differences cannot be ruled
out.
In our study we were also particularly keen to exclude
influences of IL- 1 a, which naturally occurs in patient sera, on
the anti-IL-la antibody assay. Using exogeneous IL-la we
could not demonstrate a major influence of additional IL-la on
the detection of anti-IL-i a autoantibodies. These findings are in
keeping with other authors, who reported interference of exo-
geneous IL-i a with their antibody detection method only with
100-fold doses of IL-la [15]. In our opinion, some influence on
autoantibody detection, mediated by a possible alteration of
Abbreviations are: sgf, stable graft function; GN, glomerulonephritis;
avr, acute vascular rejection.
Abbreviations are: epi, epimembraneous; ON, glomerulonephritis;
ANCA, ANCA associated vasculitis; sk, single kidney; AN, analgesic
nephropathy; PKD, polycystic kidney disease; REF, reflux nephrop-
athy.
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protein binding in uremic sera, can be excluded. Such interfer-
ences should be reflected in the autoantibody-negative chronic
renal failure patients who are without renal replacement ther-
apy and have serum creatinine values up to 12.4 mgldl.
In hemodialysis patients no association of anti-IL-i a auto-
antibodies with primary kidney disease or dialysis membranes
could be seen. However, anti-IL-i a autoantibody positive
patients showed the most pronounced increase of IL-i a serum
activity within a dialysis session. Comparing IL-i a levels of
patients treated with either cellulosic or synthetic dialyzer
membranes, this study revealed very similar post-dialysis IL-ia
values; the most striking difference in post-dialysis IL-ia levels
could be seen between anti-IL-la autoantibody positive and
negative patients. Thus, the chronic stimulation of IL-la syn-
thesis in hemodialysis patients is likely to induce the generation
of anti-IL-Ia autoantibodies seen in 32.6% of our study popu-
lation. We believe that these antibodies have a neutralizing
capacity in those patients, since adverse effects of an increased
IL-ia serum activity could not be observed in our patients.
Concerning the recently described suppressive action of IL-ia
on erythroid progenitors, which is mediated by the induction of
TNFa and can be reversed by erythropoietin [10], one would
expect any kind of interference of anti-IL-i a autoantibodies to
neutralize the inhibitory effect of IL-i a with erythropoiesis in
hemodialysis patients. In both patient groups no statistical
significant difference in erythropoietin requirement throughout
the entire study period could be seen. Therefore, it is likely that
elevated levels of anti-IL-ia autoantibodies block the possible
suppressive effect of IL-i a on erythroid progenitor targets in
patients with a pronounced increase of IL-l a activity within a
dialysis session.
In kidney graft recipients and chronic renal failure patients
only a small number of patients presented with anti-IL-la
antibodies. In the latter group three out of eight antibody
positive patients suffered from bacterial urinary tract infection.
Consequently, the detection of autoantibodies was not unex-
pected in these cases [14]. Four patients had an acute deterio-
ration of kidney function due to various diseases and the
remaining one, who was in a stable state of health, suffered
from polycystic kidney disease. Five out of the nine autoanti-
body positive kidney transplant recipients were in a stable state
of health, one patient had an acute vascular rejection, and the
remaining three suffered from progressive deterioration of graft
function due to biopsy proven glomerulonephritis. Summariz-
ing the results of chronic renal failure and kidney transplant
patients, autoantibodies could be detected in patients with
bacterial infection, and in some of the remaining cases, an acute
deterioration of graft or kidney function due to a large variety of
diseases could be observed. Thus, similarly to hemodialysis
patients, no clear association with kidney or renal graft disease
was evident, and the percentage of patients with anti-IL-la
autoantibodies was close to the normal value.
The reason for anti-IL-ia autoantibody generation is neither
clear in principle nor in the setting of hemodialysis treatment.
Bendtzen et al proposed that naturally occurring autoantibodies
against IL-i a might have a protective effect on IL-i a to reduce
urinary excretion, proteolytic degradation or binding to vessel
walls, and to function as a carrier protein to facilitate IL-ia
binding at specific high-affinity target sites. On the other hand,
extreme stimulation of the immune system may be prevented by
such antibodies, which interfere, as has been recently de-
scribed, with IL-ia binding to the receptor or with its T cell
stimulatory function [14], neutralizing adverse systemic effects
of IL-i a in various clinical settings. Such a mechanism might be
present in patients with severe bacterial infection, who very
rapidly produce anti-cytokine antibodies [i6]. Furthermore,
Suzuki et al elegantly demonstrated a neutralizing effect of
anti-IL-i a autoantibodies in sera from rheumatoid arthritis
patients [151.
Our study for the first time clearly indicates that: 1) anti-
IL-la autoantibodies are detectable in high frequency in hemo-
dialysis patients in contrast to kidney graft recipients and
chronic renal failure patients; 2) the presence of these autoanti-
bodies is not associated with primary renal disease or diaiyzer
membranes, but with 3) a more pronounced increase of IL-ia
activity in anti-IL-i a autoantibody positive hemodialysis pa-
tients; and 4) anti-IL-i a autoantibodies might have a neutraliz-
ing effect on IL-la, at least in hemodialysis patients, since no
clinical symptoms due to adverse effects of an increased IL-i a
release were present in our hemodialysis patients.
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